Randy Schatzman, the former chief executive of Alder BioPharmaceuticals (NASDAQ: [[ticker:ALDR]]), has been appointed CEO of Bolt Biotherapeutics. He is also joining the Redwood City, CA, company’s board of directors. Schatzman was CEO of Alder from its founding in 2004 until last year, when he left the company. Bolt Bio raised $54 million in February to support development of cancer immunotherapies that turn “cold” tumors into “hot” ones recognized by the immune system.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
